Takeda Pharmaceutical acquires celiac disease drug developer PvP Biologics
Takeda acquisition of PvP Biologics : Japanese pharma giant Takeda Pharmaceutical Company has acquired US-based celiac disease drug developer PvP Biologics in a deal worth ... Read More
ImmunogenX enrolls patients for Solutions for Celiac trial of Latiglutenase
ImmunogenX, a subsidiary of Immunogenics, has started enrollment of patients for a phase 2b clinical trial to evaluate Latiglutenase (IMGX003), its lead candidate for the ... Read More
PvP Biologics launches Phase 1 trials for celiac disease candidate Kuma062
PvP Biologics, a US-based pharmaceutical company, has recently begun two phase 1 clinical trials to assess the safety, tolerability, and pharmacodynamics of Kuma062, a promising ... Read More